The New Doctrine of Biological Sovereignty The appointment of Dr. Heidi Overton to lead the Food and Drug Administration (FDA) is being framed by the mainstream press as a standard political placement—a move to align a regulatory body with the ideological currents of the White House. This is a superficial reading. To view this through the lens of partisan loyalty is to miss the tectonic shift occurring beneath the surface of American governance. We are witnessing the formalization of a new doctrine: the transition of the regulatory state from a passive gatekeeper of safety to an active architect of national resilience. In the era of President Trump, the FDA is no longer merely a referee; it is becoming a strategic asset in the pursuit of biological and economic sovereignty. For decades, the FDA has operated under a consensus-driven model of risk mitigation, a hallmark of the post-WWII institutional order. This model assumed...